Psychiatric Times - Category 1 Credit
You must keep your own records of this activity. Copy this information and include it in your continuing education file for reporting purposes.
CME LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CME LLC is approved by the California Board of Registered Nursing, Provider No. CEP12748, and designates this educational activity for 1.5 contact hours for nurses.
The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ toward recertification requirements.
The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
Sponsored by CME LLC for 1.5 Category 1 credits.
Original release date 02/09. Approved for CME credit through April 2009.
• Strategies used in cognitive-behavioral therapy (CBT) for the treatment of severe mental illness
• Treatment approaches
• The benefits and challenges of using CBT
Who will benefit from reading this article?
Psychiatrists, psychologists, primary care physicians, nurse practitioners, and other health care professionals. To determine whether this article meets the continuing education requirements of your specialty, please contact your state licensing and certification boards.
1. Wright JH, Turkington D, Kingdon D, Basco M. Cognitive Therapy for
Severe Mental Illness: An Illustrative Manual. Arlington, VA: American
Psychiatric Publishing, Inc; 2008.
2. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for
schizophrenia: effect sizes, clinical models, and methodological rigor.
Schizophr Bull. 2008;34:523-537.
3. Rathod S, Kingdon D, Smith P, Turkington D. Insight into schizophrenia:
the effects of cognitive behavioural therapy on the components
of insight and association with sociodemographics—data on a previously
published randomised controlled trial. Schizophr Res. 2005;
4. American Psychiatric Association Steering Committee on Practice
Guidelines. American Psychiatric Association Practice Guidelines for the
Treatment of Psychiatric Disorders Compendium 2006.Washington, DC:
American Psychiatric Association; 2006.
5. National Institute for Clinical Excellence. Clinical Guideline: Schizophrenia
(Clinical Guideline 1). London: Department of Health; 2002.
6. Kingdon DG, Turkington D. Cognitive Therapy of Schizophrenia. New
York: Guilford; 2005.
7. Turkington D, Sensky T, Scott J, et al. A randomized controlled trial
of cognitive-behavior therapy for persistent symptoms in schizophrenia:
a five-year follow-up. Schizophr Res. 2008;98:1-7.
8. Rathod S. Expansion of psychological therapies. Br J Psychiatry.
9. Lancashire S. Revised Version of the KGV Scale. Manchester, UK: University
of Manchester; 1994.
10. Birchwood M, Smith J, Cochrane R, et al. The Social Functioning
Scale: the development and validation of a new scale of social adjustment
for use in family intervention programmes with schizophrenic patients.
Br J Psychiatry. 1990;157:853-859.
11. Chadwick P, Birchwood M.The omnipotence of voices, II: the Beliefs
About Voices Questionnaire (BAVQ). Br J Psychiatry. 1995;166:773-776.
Kingdon DG, Turkington D. Cognitive Therapy of Schizophrenia. New
York: Guilford Press; 2005.
Wright JH, Turkington D, Kingdon DG, Basco M. Cognitive Behaviour
Therapy for Severe Mental Illness: An Illustrated Guide. Arlington, VA:
American Psychiatric Publishing, Inc; 2008.